{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:14:21Z","timestamp":1714004061328},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.canlet.2012.05.032","type":"journal-article","created":{"date-parts":[[2012,6,6]],"date-time":"2012-06-06T03:08:10Z","timestamp":1338952090000},"page":"18-25","source":"Crossref","is-referenced-by-count":1,"title":["Suboptimal response in chronic myeloid leukemia patients treated with imatinib: Early identification and new therapeutic challenges"],"prefix":"10.1016","volume":"325","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2012.05.032_b0005","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia \u2013 advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.canlet.2012.05.032_b0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the c-Abl and Bcr\u2013Abl tyrosine kinases","volume":"5","author":"Hantschel","year":"2004","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.canlet.2012.05.032_b0015","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"European LeukemiaNet. Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2012.05.032_b0020","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.canlet.2012.05.032_b0025","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr\u2013abl1 positive chronic myeloid leukaemia","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.05.032_b0030","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.hoc.2004.03.008","article-title":"Biology of chronic myelogenous leukaemia-signaling pathways of initiation and transformation","volume":"18","author":"Melo","year":"2004","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.canlet.2012.05.032_b0035","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/cncr.11520","article-title":"Chronic myelogenous leukaemia: a review and update of therapeutic strategies","volume":"98","author":"Garcia-Manero","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2012.05.032_b0040","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR\u2013ABL tyrosine kinase in chronic myeloid leukaemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.canlet.2012.05.032_b0045","first-page":"1972","article-title":"Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase","volume":"9","author":"Johnson","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2012.05.032_b0050","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukaemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.05.032_b0055","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.186.186","article-title":"Low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM)","volume":"112","author":"O\u2019Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.05.032_b0060","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.05.032_b0065","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations fron an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.05.032_b0070","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.canlet.2012.05.032_b0075","doi-asserted-by":"crossref","first-page":"i52","DOI":"10.1093\/annonc\/mdi807","article-title":"ESMO guidelines task force. ESMO minimum clinical recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML)","volume":"16","author":"Simonsson","year":"2005","journal-title":"Ann. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.canlet.2012.05.032_b0080","first-page":"S29","article-title":"Update: chronic myelogenous leukemia clinical practice guidelines","volume":"1","author":"O\u2019Brien","year":"2003","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.canlet.2012.05.032_b0085","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2012.05.032_b0090","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.05.032_b0095","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual out come is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.05.032_b0100","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.24418","article-title":"Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase","volume":"115","author":"Alvarado","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2012.05.032_b0105","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood.V114.22.2196.2196","article-title":"Chronic myeloid leukemia (CML) patients with \u201csuboptimal\u201d response to imatinib (IM) according to European LeukemiaNet criteria have a poorer outcome with respect to \u201coptimal\u201d responders: a GIMEMA CML Working Party analysis","volume":"114","author":"Castagnetti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.05.032_b0110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2141.2010.08380.x","article-title":"Suboptimal response to imatinib according to 2006\u20132009 European LeukemiaNet criteria: a \u201cgrey zone\u201d at 3, 6 and 12months identifies chronic myeloid leukemia patients who need early intervention","volume":"152","author":"Breccia","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2012.05.032_b0115","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"IRIS investigators. Five-years follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2009","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.canlet.2012.05.032_b0120","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"ENESTnd Investigators. Nilotinib vs imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.canlet.2012.05.032_b0125","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800mg\/d vs 400mg\/d vs 400mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2012.05.032_b0130","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"SPIRIT investigators; France intergroupe des leuc\u00e9mies my\u00e9lo\u00efdes chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2\u00b0 in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.canlet.2012.05.032_b0135","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2012.05.032_b0140","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"International randomised study of interferon versus STI571 (IRIS) study group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.canlet.2012.05.032_b0145","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1002\/cncr.11831","article-title":"Imatinib mesylate therapy improbe survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2012.05.032_b0150","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2008-06-161737","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.05.032_b0155","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.05.032_b0160","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2003-06-2042","article-title":"Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses","volume":"102","author":"Marin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.05.032_b0165","first-page":"2092","article-title":"The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadeguate hematologic or cytogenetic response to initial treatment","volume":"9","author":"Zonder","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2012.05.032_b0170","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","article-title":"International Randomized Study of Interferon and STI571 (IRIS) investigators. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2012.05.032_b0175","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard \u2013 dose imatinib therapy","volume":"113","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.05.032_b0180","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/leu.2009.32","article-title":"Imatinib dose escalation for chronic phase-chronic myelogenous leukemia patients in primary suboptimal response to imatinib 400mg daily standard therapy","volume":"23","author":"Rea","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2012.05.032_b0185","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.21680","article-title":"Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukemia patients at 3-year follow-up","volume":"85","author":"Breccia","year":"2010","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2012.05.032_b0190","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3324\/haematol.2009.013979","article-title":"High-dose imatinib improbe cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR\u2013ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 \u201cHISTAHIT\u201d study","volume":"95","author":"Petzer","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2012.05.032_b0195","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2009.021154","article-title":"Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group","volume":"95","author":"Cervantes","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2012.05.032_b0200","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood.V118.21.452.452","article-title":"Nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 36-month follow-up","volume":"118","author":"Saglio","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.05.032_b0205","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cncr.26249","article-title":"Expanding nilotinib access in clinical trials (ENACTs): an opne-label, multi center study of oral nilotinib in adult patients with imatinib-esistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase","volume":"118","author":"Nicolini","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2012.05.032_b0210","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood.V118.21.2771.2771","article-title":"Effect of nilotinib on molecular response in chronic myelogenous leukemia-chronic phase (CML-CP) patients with suboptimal molecular response to imatinib-ENABL study update","volume":"118","author":"Ailawadhi","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.canlet.2012.05.032_b0215","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.V118.21.451.451","article-title":"Upfront imatinib therapy in CML patients with rapid switching to nilotinib for failure to achieve molecular targets or intolerance achieves high overall rates of molecular response and a low risk progression \u2013 an update of the TIDEL-II trial","volume":"11","author":"Yeung","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.05.032_b0220","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/blood.V118.21.114.114","volume":"118","author":"Hochhaus","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.05.032_b0225","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood.V118.21.606.606","volume":"118","author":"Hughes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.05.032_b0230","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood.V118.21.2765.2765","article-title":"Efficacy of nilotinib versus high dose imatinib in early chronic phase CML patients who have suboptimal molecular responses to standard-dose imatinib (RE-NICE multi center study)","volume":"118","author":"Goh","year":"2011","journal-title":"Blood"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383512003515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383512003515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T23:29:19Z","timestamp":1714001359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383512003515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0304383512003515"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2012.05.032","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}